Can-Fite BioPharma Ltd.CANF
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE American · Israel · canfite.com
Can-Fite BioPharma Ltd. is an advanced clinical-stage drug development company with a platform technology targeting cancer, liver and inflammatory disease. Its lead candidate Piclidenoson is in a pivotal Phase 3 trial for psoriasis; its liver drug Namodenoson is in Phase 3 for hepatocellular carcinoma, Phase 2b for MASH and Phase 2a in pancreatic cancer. A third candidate, CF602, targets erectile dysfunction.
Key ratios
FCF / Sales
-2348.9%TTM
2025
-2210.1%2024
-1133.8%2023
-1136.2%
ROA
-77.1%TTM
2025
-66.8%2024
-53.2%2023
-53.2%
ROE
-211.4%TTM
2025
-178.2%2024
-134.9%2023
-142.5%
Revenue growth
-27.7%TTM
2025
-39.9%2024
-9.3%2023
-8.3%
Recent news
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Track CANF in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer